Dicynone 500 mg 14 tablets

Tradename:

Dicynon

Dicynone

Compound:

Each tablet contains:

Ethamsylate 500 mg

Auxiliary components:

Starch, microcrystalline cellulose, polyvinylpyrrolidone, stearic acid, sodium dihydrogen citrate, anhydrous sodium sulfate.

Properties:

Hemostatic agent, also has an angioprotective and proaggregant effect. Stimulates the formation of platelets and their exit from the bone marrow. The hemostatic effect, due to the activation of thromboplastin formation at the site of damage to small vessels and a decrease in the formation of prostacyclin PgI2 in the vascular endothelium, contributes to an increase in platelet adhesion and aggregation, which ultimately leads to a stop or a decrease in bleeding. Increases the rate of formation of the primary thrombus and enhances its retraction, has virtually no effect on the concentration of fibrinogen and prothrombin time.

Indications:

– Prevention and control of hemorrhages in superficial and internal capillaries of various etiologies, especially if bleeding is caused by endothelial damage;

– Prevention and treatment of bleeding during and after surgical operations in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery;

– Prevention and treatment of capillary bleeding of various etiology and localization;

-Hematuria, metrorrhagia, primary hypermenorrhea, hypermenorrhea in women with intrauterine contraceptives, epistaxis, bleeding gums.

Dosage and administration:

Applied inside. Tablets are taken during or after meals with a small amount of water. Before surgery, take 1 tablet (500 mg) 1 hour before surgery. After surgery, take 1 tablet (500 mg) every 4-6 hours until the risk of bleeding disappears. For menorrhagia, take 1 tablet 3 times a day (1500 mg) for 10 days, starting on the 5th day from the expected onset of menstruation until the 5th day of the next menstrual cycle. The daily dose for children is half the dose for adults.

Contraindications:

Hypersensitivity to etamsylate or any other component of the drug, acute porphyria, thrombosis, thromboembolism, increased blood clotting. Hemoblastosis (lymphatic and myeloid leukemia, osteosarcoma) in children.

Precautionary measures:

Use with caution in patients with a history of thrombosis or thromboembolism. The drug is ineffective with a reduced number of platelets. In hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes. Other causes of bleeding should be ruled out before starting treatment.

Side effects:

– From the side of the nervous system: headache, dizziness, hot flashes, paresthesia of the lower extremities.

– From the digestive system: nausea, vomiting, diarrhea, abdominal discomfort.

– From the immune system: hypersensitivity, allergic reactions, skin rash, urticaria, itching, a case of angioedema is described.

– From the musculoskeletal system: arthralgia.

– From the circulatory and lymphatic system: agranulocytosis, neutropenia, thrombocytopenia.

– From the vascular system: thromboembolism.

Others: asthenia, fever, acute porphyria. All side effects are mild and transient. Children who used etamsylate to prevent bleeding in acute lymphatic and myeloid leukemia were more likely to have severe leukopenia.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains 2 blisters of 7 tablets, paper instructions.